Effects of Renal Impairment and Inclisiran

Dr. R. Scott Wright, a Cardiologist at Mayo Clinic in Rochester, MN, and investigator in the ORION-7 and ORION-I Studies, shares results in his article appearing in the January 2020 issue of Mayo Clinic Proceedings, where he notes that a reduction in cholesterol greater than 50% was noted in patients taking Incliseran - a small interfering RNA (siRNA) targeting PCSK9 - even when the patient had mild, moderate, or severe renal impairment, and the effects of the drug were similar in all subjects making it safe and effective for use without need for dose adjustments. Available at: mayocl.in/2rvpFZ2